Proven Effectiveness in Maintaining Bone Mineral Density in the Lumbar Spine and Femur
Research findings have been announced showing that Yuyu Pharmaceutical's osteoporosis treatment, Maxmarvil Jang Yongjung, can be usefully utilized as a sequential treatment option to maintain bone density after discontinuation of denosumab.
Professor Hyojung Kim from Eulji University College of Medicine recently presented research findings at the Korean Society for Bone and Mineral Research international conference 'SSBH 2025,' showing that Maxmarvil Jang Yongjung can be usefully utilized as a sequential treatment option to maintain bone density after discontinuation of denosumab. Yuyu Pharmaceutical
Professor Hyojung Kim from Eulji University College of Medicine recently stated at the Korean Society for Bone and Mineral Research international conference SSBH 2025 that, in a study involving 360 postmenopausal osteoporosis patients, the maintenance of bone mineral density was observed when various antiresorptive agents were administered after an average of 4.2 doses of denosumab. In particular, in the group receiving the combination of low-dose alendronate and calcitriol, there was no statistically significant decrease in bone mineral density in the lumbar spine, femoral neck, or total hip regions.
On the other hand, in the group switched to selective estrogen receptor modulators, bone mineral density in all measured regions decreased significantly compared to the other treatment groups. In the group switched to ibandronate, bone mineral density decreased statistically significantly in both the lumbar spine and femoral neck, while in the group switched to risedronate, a significant decrease was observed only in the femoral neck.
Professor Hyojung Kim said, "This is the largest retrospective study investigating treatment effects after discontinuation of denosumab, and it is significant in that it provides real-world data focused on the Asian population. In particular, by demonstrating that the combination of low-dose alendronate and calcitriol is effective in maintaining bone mineral density in the lumbar spine, femoral neck, and total hip, we have provided useful clinical evidence to help select alternative medications after discontinuing denosumab treatment."
Yuyu Pharmaceutical's osteoporosis treatment, 'Maxmarvil Jang Yongjung,' is an improved combination drug containing low-dose alendronate (5mg) and the active form of vitamin D, calcitriol. Maxmarvil Jang Yongjung is developed as an enteric-coated tablet using a dual-granule method to enhance bioavailability, dissolving in the intestine rather than the stomach, which reduces esophageal and gastrointestinal side effects compared to other bisphosphonate formulations. Due to these characteristics of the enteric-coated formulation, both preprandial and postprandial administration significantly increased BMD.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
